This seems like it would be classified as a major change from a project management and regulatory perspective, especially since it affects a functional aspect of the device and involves different international regulatory requirements. I’d assume this would trigger steps like risk analysis, process validation, and possibly updated submissions for EU approval. But I’m curious—would companies usually start those steps before halting or changing production, or try to validate in parallel to avoid interruptions? From what I’ve seen, though my experience isn’t in the EU, larger companies sometimes manage different product variations by region, like using different coatings or sterilization methods depending on local regulations. I imagine there’s usually a cost-benefit analysis or market evaluation to decide whether adapting to a second market is worth the effort and resources to build a separate production line. 

Switching the sterilization method of a medical device from gamma radiation to ethylene oxide (EtO) to meet European Medicines Agency (EMA) requirements would be classified as a major change from both a project management and regulatory perspective. Since the sterilization process directly impacts the device’s surface properties—a functional characteristic—it would trigger comprehensive validation activities, regulatory submissions, and risk assessments.

To implement this change without disrupting current production, the company could follow a phased parallel validation approach:

1. Risk Assessment and Feasibility Study: Perform a detailed risk analysis (e.g., FMEA) to evaluate how the switch to EtO could affect the device's material integrity, biocompatibility, and performance. Assess whether the facility’s current EtO sterilization capacity can handle the additional volume without affecting existing production lines.

2. Parallel Validation and Testing: Instead of halting production, the company could create a pilot or parallel validation line dedicated to the EtO-sterilized product. This allows the company to continue US distribution using gamma radiation while simultaneously validating the new sterilization process for the EU market. Key activities during validation would include bioburden testing, residual analysis, and sterility assurance level (SAL) verification.

3. Regulatory Submissions: Submit the new sterilization process validation data to the EMA for approval. If successful, the EU-dedicated EtO-sterilized batch could be produced without interfering with US distribution.

4. Cost-Benefit and Market Evaluation: Since running dual sterilization processes can be resource-intensive, the company should conduct a cost-benefit analysis to determine whether maintaining separate production lines for different regions is sustainable.

5. Gradual Transition with Dual Inventory: If the EtO method proves more efficient or gains regulatory preference, the company may eventually transition all production to EtO. However, during the initial phase, running dual sterilization processes ensures continuous production while meeting distinct regional requirements.

By validating the new process in parallel and using dedicated production lines, the company can minimize disruptions, comply with EU regulations, and avoid unnecessary downtime in its US operations.

Changes are frequently required during the development of medical devices, whether they are precipitated by regulatory updates, design enhancements, or supplier modifications. However, it is imperative that these modifications be executed with precision to prevent production disruptions or compliance violations.  Establishing a strong change control system is among the main tactics. This guarantees that all changes are reviewed for their impact on safety, performance, and regulatory paperwork prior to implementation. This assessment is necessary to determine whether new verification or validation is necessary, even for minor modifications such as material substitutions.

Coordination and timeliness provide the primary difficulties. Delays, revisions, or even product recalls may result from introducing a change too late in the production process. The supply chain is maintained stable and the transition is managed seamlessly by involving the quality, regulatory, and manufacturing teams at an early stage. How can teams balance the need to always get better with the risks of making changes in the middle of a project? Should businesses give rigorous controls first priority in order to reduce disturbance or allow more manufacturing flexibility and innovation?

I agree that this would be quite a significant change, particularly because it affects a critical process that could alter the device's biocompatibility, functionality, or performance. To implement the change without interrupting current production, I would second that the company should maintain parallel processes—continuing gamma sterilization for U.S. distribution while validating EtO sterilization for the EU. This would involve updating the design history file, conducting a risk assessment, performing verification and validation testing, and submitting regulatory documentation to the EMA. If facilities are already equipped for EtO, downtime could be minimized, though there may be a brief transition period to ensure proper validation and quality control before full-scale production for EU markets begins. Parallel processes would allow this change to occur whilst minimizing interruptions to current production. 

I also agree that this qualifies as a major change in the device. If the EMA is questioning whether the current method to sterilize is safe and whether it changes the surface of the product, which you claimed is very important to the device, then this issue is in the formal change control territory. I would not immediately shut down the current production because the product is already cleared in the United States, meaning there is some support for the safety and feasibility of gamma sterilization. Stopping all production would disrupt many different areas and cause chaos. If there were data that showed a real safety issue, then shutting down production would make sense. This brings in the concern that two major regulators are interpreting the same device differently. Was the original surface characterization data flawed for this to happen? I think the leadership should first evaluate whether the surface texture claim needs to be addressed globally or just reframed for the EU. 

If the latter is the case, I would treat the issue as a region-specific modification and do a parallel validation for it. Switching to ethylene oxide means you would have to revalidate the sterilization from the start. You would need to test sterility again, residual testing, and now also confirm that the material properties and surface are unchanged after sterilization. Ethylene oxide also adds aeration time, environmental controls, and scheduling issues that are different from gamma sterilization. 

As a PM, I would keep production running in the US and create a new pathway for EU products. This would reduce revenue risks and give the company peace of mind and room to validate properly instead of rushing to get the product out in the market again. The main issue later becomes whether to standardize all the devices and switch to ethylene oxide or keep two separate pipelines. Harmonizing everything would require reopening with the FDA and a whole new approval process, although it would go faster with prior experience and approval of the product beforehand. This reminds me of how Apple had to change all its iPhones to USB-C with the new laws in Europe. However, changing the sterilization could affect marketing and how the device is commercially positioned. Labelling, promotional claims, and other materials need to be changed by the marketing team as well. Additionally, a change in sterilization method can change the company’s liability profile. Insurance providers may reassess the risk of the product when there are changes in sterilization. If you were in leadership, would you want to have your product globally harmonized even if it means some regulatory friction in the U.S., or would you have regional divergence? How would you combat the cascading effects in the U.S., as I mentioned above? How could AI be integrated to speed up any of these processes? At what point does the hassle of harmonization outweigh the benefits?

As many others have mentioned, this would be considered a major change. If a product failed to meet the regulations needed by the country in which the product would be sold in, this is something that would most likely be caught in the very beginning of the project. Well before you get to the stage of production. Companies often have staff that specialize in regulations that would identify early on in a project what would be needed in order to ensure that the project proceeds smoothly and meets all regulations. 

Though unlikely, this kind of oversight, is not impossible. Or another way to look at it is that this kind of change could also be a spec change request from the customer--they want this now done differently for their device. In the case where the cleaning method of the device has to be changed, there would need to be verification and validation done separately to ensure that the new method meets all regulations and are proved to be safe for human use. Additionally, there would need to be investigation done into whether the 'old' method was unsafe--is there a negative effect on a person using the device due to the surface being unsmooth? Depending on those results, the previous method used could be a major quality finding. 

All production would have to be halted until this was well understood and the new method was put in place.

I really appreciate all the insights shared here, especially the idea of running parallel validation to minimize production disruptions. Building on Dev Doshi’s point about regional divergence, one thing I’d add is considering how AI and digital twin simulations could speed up the validation process. For instance, simulating EtO sterilization on virtual models of the device could predict surface effects before physical testing, reducing trial-and-error in the lab. I also think there’s an interesting strategic angle regarding global harmonization vs. regional differentiation. Harmonizing all production to EtO could simplify regulatory filings long-term but might introduce short-term delays or FDA re-approval requirements. Maintaining separate pipelines is operationally complex but allows continued US distribution without interruption.